Mast Therapeutics Price Prediction

  
Investment Horizon     30 Days    Login   to change
With this module your can estimate the value of Mast Therapeutics Inc from the prospective of Mast Therapeutics response to recently generated media hype and the effects of current headlines on its competitors. The module also provides analysis of price elasticity to changes in media outlook on Mast Therapeutics over a specific investment horizon. See also Mast Therapeutics Backtesting, Mast Therapeutics Volatility, Mast Therapeutics Valuation, Mast Therapeutics Correlation, Mast Therapeutics History and Mast Therapeutics Performance

Mast Therapeutics estimiated after-hype price volatility

Next price density
 
Embed  
Expected price to next headline
May 2, 2016
0.29
Current Value
Downside upside
Downside
0.01
0.29
After-hype Price
10.76
Upside
Upside upside
Mast Therapeutics is exceptionally risky asset. Analysis and calculation of next after-hype price of Mast Therapeutics is based on 1 month time horizon.

Mast Therapeutics Hype Analysis

Daily Expected returnPeriod VolatilityHype elasticityRelated hype elasticityAverage news densityRelated news densityNext Expected Hype
 0.23% 3.49% 0.00%  0.03% 1 Events / Month6 Events / MonthUncertain
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
0.290.290.03%
0.00% 

Mast Therapeutics Hype Timeline

Mast Therapeutics Inc is now traded for 0.29 . This company stock is not elastic to its hype. The average elasticity to hype of competition is -0.03. Mast Therapeutics Inc is projected to decline in value after the next headline with price expected to drop to 0.29. The average volatility of media hype impact on the company stock price is about 0.0%. The price decrease on the next news is expected to be -0.03% where as daily expected return is now at 0.23%. The volatility of related hype on Mast Therapeutics is about 2475.18% with expected price after next announcement by competition of 0.26. About 23.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.51. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Mast Therapeutics Inc recorded loss per share of 0.24. This company had not issued any dividends in recent years. The firm had 1:25 split on April 26, 2010. Given the investment horizon of 30 days, the next projected press release will be uncertain.
See also Mast Therapeutics Backtesting, Mast Therapeutics Volatility, Mast Therapeutics Valuation, Mast Therapeutics Correlation, Mast Therapeutics History and Mast Therapeutics Performance

Mast Therapeutics Related Hype Analysis

Hype
Elasticity
News
Dencity
Semi
Deviation
Information
Ratio
Expected
Short fall
Potential
Upside
Value
At Risk
Maximum
Drawdown
Gilead Sciences Inc(0.11)2 per month 0.00 (0.14) 0.00  1.63 (3.72) 11.00 
Amgen Inc 1.30 3 per month 0.73  0.04 (0.86) 1.41 (1.41) 5.82 
Celgene Corporation(1.66)3 per month 1.76  0.04 (1.54) 2.99 (2.73) 10.25 
Biogen Inc(2.10)3 per month 1.31  0.07 (1.87) 5.16 (2.15) 7.59 
Regeneron Pharmaceuticals Inc(7.60)3 per month 0.00 (0.12) 0.00  3.85 (3.73) 9.86 
Alexion Pharmaceuticals Inc 1.95 2 per month 0.00 (0.05) 0.00  3.83 (5.47) 11.80 
Baxalta Incorporated(0.05)2 per month 2.28  0.03 (1.48) 2.59 (1.45) 9.22 
Illumina Inc 4.96 2 per month 0.00 (0.16) 0.00  3.92 (3.42) 29.53 
Vertex Pharmaceuticals Incorporated 1.80 3 per month 2.76  0.05 (2.83) 4.70 (5.49) 14.62 
Incyte Corporation 0.10 3 per month 1.60  0.0013 (3.09) 2.89 (2.77) 14.63